(NBIX) Neurocrine Biosciences - Ratings and Ratios
Pharmaceuticals, Neurology, Endocrinology, Neuropsychiatry, Therapeutics
NBIX EPS (Earnings per Share)
NBIX Revenue
Description: NBIX Neurocrine Biosciences
Neurocrine Biosciences Inc. is a biotechnology company focused on developing and marketing pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders. The companys product portfolio includes approved treatments for conditions such as tardive dyskinesia, Huntingtons disease, adrenal insufficiency, endometriosis, and uterine fibroids.
From a business perspective, Neurocrine Biosciences has a diverse pipeline of product candidates in clinical development, targeting a range of conditions including movement disorders, schizophrenia, and major depressive disorder. The companys partnerships with major pharmaceutical companies such as AbbVie and Takeda Pharmaceutical Company Limited demonstrate its ability to collaborate and leverage its research and development capabilities.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, product adoption rates, and clinical trial success rates are crucial. Notably, the companys return on equity (RoE) of 11.81% indicates a relatively strong ability to generate profits from shareholder equity. Additionally, the forward price-to-earnings ratio (P/E Forward) of 26.18 suggests that the market expects the company to grow its earnings in the future.
Further analysis of Neurocrine Biosciences financials and operational metrics reveals that its market capitalization stands at $13.35 billion, indicating a significant presence in the biotechnology sector. The companys ability to expand its product portfolio and successfully commercialize its treatments will be critical in driving future growth and creating value for shareholders.
NBIX Stock Overview
| Market Cap in USD | 14,242m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1996-05-23 |
NBIX Stock Ratings
| Growth Rating | 45.1% |
| Fundamental | 80.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -1.55% |
| Analyst Rating | 4.48 of 5 |
NBIX Dividends
Currently no dividends paidNBIX Growth Ratios
| Growth Correlation 3m | 73.6% |
| Growth Correlation 12m | 27.9% |
| Growth Correlation 5y | 72.1% |
| CAGR 5y | 10.66% |
| CAGR/Max DD 3y | 0.25 |
| CAGR/Mean DD 3y | 0.81 |
| Sharpe Ratio 12m | 1.14 |
| Alpha | 0.17 |
| Beta | 0.243 |
| Volatility | 28.17% |
| Current Volume | 611.7k |
| Average Volume 20d | 674.6k |
| Stop Loss | 138.4 (-3%) |
| Signal | 0.82 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (348.3m TTM) > 0 and > 6% of Revenue (6% = 150.6m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA -1.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 47.91% (prev 59.98%; Δ -12.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 567.3m > Net Income 348.3m (YES >=105%, WARN >=100%) |
| Net Debt (175.1m) to EBITDA (557.2m) ratio: 0.31 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (101.0m) change vs 12m ago -2.79% (target <= -2.0% for YES) |
| Gross Margin 98.49% (prev 98.28%; Δ 0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.77% (prev 64.13%; Δ 5.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.18 (EBITDA TTM 557.2m / Interest Expense TTM 126.6m) >= 6 (WARN >= 3) |
Altman Z'' 3.17
| (A) 0.31 = (Total Current Assets 1.75b - Total Current Liabilities 546.3m) / Total Assets 3.89b |
| (B) 0.02 = Retained Earnings (Balance) 84.5m / Total Assets 3.89b |
| (C) 0.15 = EBIT TTM 528.7m / Avg Total Assets 3.60b |
| (D) 0.08 = Book Value of Equity 97.1m / Total Liabilities 1.20b |
| Total Rating: 3.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.35
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.66% = 1.83 |
| 3. FCF Margin 21.06% = 5.27 |
| 4. Debt/Equity 0.44 = 2.40 |
| 5. Debt/Ebitda 2.15 = -0.29 |
| 6. ROIC - WACC (= 7.14)% = 8.93 |
| 7. RoE 13.22% = 1.10 |
| 8. Rev. Trend 96.43% = 7.23 |
| 9. EPS Trend 47.56% = 2.38 |
What is the price of NBIX shares?
Over the past week, the price has changed by +1.05%, over one month by +7.20%, over three months by +14.29% and over the past year by +16.70%.
Is Neurocrine Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NBIX is around 138.98 USD . This means that NBIX is currently overvalued and has a potential downside of -2.63%.
Is NBIX a buy, sell or hold?
- Strong Buy: 15
- Buy: 7
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NBIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 168.3 | 17.9% |
| Analysts Target Price | 168.3 | 17.9% |
| ValueRay Target Price | 152.8 | 7% |
Last update: 2025-09-12 04:41
NBIX Fundamental Data Overview
CCE Cash And Equivalents = 975.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 42.6113
P/E Forward = 27.1003
P/S = 5.6745
P/B = 5.2861
P/EG = 0.2733
Beta = 0.283
Revenue TTM = 2.51b USD
EBIT TTM = 528.7m USD
EBITDA TTM = 557.2m USD
Long Term Debt = 649.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 546.3m USD (from totalCurrentLiabilities, last quarter)
Debt = 1.20b USD (Calculated: Short Term 546.3m + Long Term 649.2m)
Net Debt = 175.1m USD (from netDebt column, last quarter)
Enterprise Value = 14.46b USD (14.24b + Debt 1.20b - CCE 975.6m)
Interest Coverage Ratio = 4.18 (Ebit TTM 528.7m / Interest Expense TTM 126.6m)
FCF Yield = 3.66% (FCF TTM 528.7m / Enterprise Value 14.46b)
FCF Margin = 21.06% (FCF TTM 528.7m / Revenue TTM 2.51b)
Net Margin = 13.88% (Net Income TTM 348.3m / Revenue TTM 2.51b)
Gross Margin = 98.49% ((Revenue TTM 2.51b - Cost of Revenue TTM 37.8m) / Revenue TTM)
Tobins Q-Ratio = 148.9 (set to none) (Enterprise Value 14.46b / Book Value Of Equity 97.1m)
Interest Expense / Debt = 10.59% (Interest Expense 126.6m / Debt 1.20b)
Taxrate = 29.77% (144.7m / 486.0m)
NOPAT = 371.3m (EBIT 528.7m * (1 - 29.77%))
Current Ratio = 3.20 (Total Current Assets 1.75b / Total Current Liabilities 546.3m)
Debt / Equity = 0.44 (Debt 1.20b / last Quarter total Stockholder Equity 2.69b)
Debt / EBITDA = 2.15 (Net Debt 175.1m / EBITDA 557.2m)
Debt / FCF = 2.26 (Debt 1.20b / FCF TTM 528.7m)
Total Stockholder Equity = 2.63b (last 4 quarters mean)
RoA = 8.95% (Net Income 348.3m, Total Assets 3.89b )
RoE = 13.22% (Net Income TTM 348.3m / Total Stockholder Equity 2.63b)
RoCE = 16.10% (Ebit 528.7m / (Equity 2.63b + L.T.Debt 649.2m))
RoIC = 14.09% (NOPAT 371.3m / Invested Capital 2.63b)
WACC = 6.95% (E(14.24b)/V(15.44b) * Re(6.91%)) + (D(1.20b)/V(15.44b) * Rd(10.59%) * (1-Tc(0.30)))
Shares Correlation 3-Years: 48.48 | Cagr: 0.18%
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈515.1m ; Y1≈635.4m ; Y5≈1.08b
Fair Price DCF = 185.9 (DCF Value 18.44b / Shares Outstanding 99.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 47.56 | EPS CAGR: 37.30% | SUE: 0.49 | # QB: 0
Revenue Correlation: 96.43 | Revenue CAGR: 23.14% | SUE: N/A | # QB: None
Additional Sources for NBIX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle